At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 46 enrolled
Drug / intervention
Bromfenac +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Control of Pain in Intravitreal Injections (COPIVIN Study): A Study Evaluating the Use of Combination Topical Anesthetic and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
In Brief
A Phase 4 clinical trial evaluating Bromfenac and Artificial tears for Intravitreal Injections and IVI. Completed, enrolled 46 participants across 1 site.
Detailed Summary
Intravitreal injections (IVI) are a common form of treatment for multiple retinal pathologies. The investigators hypothesize that an intervention with a topical NSAID will alleviate pain experienced at intravitreal injection (IVI) and post-IVI. 46 participants will be recruited, randomized into 1 of 3 treatment arms, and can expect to be on study for a day.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntravitreal Injections, IVI
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
Enrollment StartJun 2019
Primary CompletionDec 2019
First PostedApr 2020
TodayJul 2026
First PostedApr 13, 2020
Enrollment StartJun 27, 2019
Primary CompletionDec 19, 2019
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.2 years ago
Interventions
Bromfenacdrug
An NSAID used to treat eye pain and swelling
Artificial tearsdrug
eye drops to lubricate the eye and maintain moisture